NLSP NLS Pharmaceutics
Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)
28 Dec 21
The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
Alexander C. Zwyer, Lewis P. Amsel, Virginia Schmith, Scott Brantley
Filed: 8 Mar 17
Mazindol Treatment for Heroin Dependence and Substance Use Disorder
3 Jun 21
The present invention relates to mazindol for use in the treatment of dependence and substance use disorder, wherein the substance is an opioid, a composition comprising mazindol and optionally a pharmaceutically acceptable carrier or excipient and/or a diluent, for use in the treatment of substance abuse disorder, wherein the substance is an opioid, and a method of treatment of substance abuse disorder comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid.
Alexander C. Zwyer
Filed: 6 Sep 18
Mazindol Combination In the Treatment of Attention-deficit/hyperactivity
1 Apr 21
The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol.
Filed: 9 Oct 20
Patents are sorted by USPTO publication date, most recent first